|
1.
|
Li H, DeRosier DJ, Nicholson WV, Nogales E
and Downing KH: Microtubule structure at 8 Å resolution. Structure.
10:1317–1328. 2002.
|
|
2.
|
Mitchison T and Kirschner M: Dynamic
instability of microtubule growth. Nature. 312:237–242. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lobert S, Vulevic B and Correia JJ:
Interaction of vinca alkaloids with tubulin: a comparison of
vinblastine, vincristine, and vinorelbine. Biochemistry.
35:6806–6814. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Burkhart CA, Berman JW, Swindell CS and
Horwitz SB: Relationship between the structure of taxol and other
taxanes on induction of tumor necrosis factor-alpha gene expression
and cytotoxicity. Cancer Res. 54:5779–5782. 1994.PubMed/NCBI
|
|
5.
|
Bazley LA and Gullick WJ: The epidermal
growth factor receptor family. Endocr Relat Cancer. 12:S17–S27.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Normanno N, Bianco C, Strizzi L, et al:
The ErbB receptors and their ligands in cancer: an overview. Curr
Drug Targets. 6:243–257. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Arnold D and Seufferlein T: Targeted
treatments in colorectal cancer: state of the art and future
perspectives. Gut. 59:838–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Gao YS, Hubbert CC and Yao TP: The
microtubule-associated histone deacetylase 6 (HDAC6) regulates
epidermal growth factor receptor (EGFR) endocytic trafficking and
degradation. J Biol Chem. 285:11219–11226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Deribe YL, Wild P, Chandrashaker A, et al:
Regulation of epidermal growth factor receptor trafficking by
lysine deacetylase HDAC6. Sci Signal. 2:ra842009.PubMed/NCBI
|
|
12.
|
Devesa SS, Blot WJ and Fraumeni JF Jr:
Changing patterns in the incidence of esophageal and gastric
carcinoma in the United States. Cancer. 83:2049–2053. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Gebski V, Burmeister B, Smithers BM, Foo
K, Zalcberg J and Simes J: Survival benefits from neoadjuvant
chemoradiotherapy or chemotherapy in oesophageal carcinoma: a
meta-analysis. Lancet Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Jankowski J HD, Hopwood D and Wormsley KG:
Expression of epidermal growth factor, transforming growth factor
alpha and their receptor in gastro-oesophageal diseases. Dig Dis.
11:1–11. 1993.
|
|
15.
|
Gibault L, Metges JP, Conan-Charlet V, et
al: Diffuse EGFR staining is associated with reduced overall
survival in locally advanced oesophageal squamous cell cancer. Br J
Cancer. 93:107–115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Kim LW, Tsung-Teh W, In Seon C, et al:
Expression of epidermal growth factor receptor in esophageal and
esophagogastric junction adenocarcinomas. Cancer. 109:658–667.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Wei Q, Chen L, Sheng L, Nordgren H, Wester
K and Carlsson J: EGFR, HER2 and HER3 expression in esophageal
primary tumours and corresponding metastases. Int J Oncol.
31:493–499. 2007.PubMed/NCBI
|
|
18.
|
Oku K, Tanaka A, Yamanishi H, et al:
Effects of various growth factors on growth of a cloned human
esophageal squamous cancer cell line in a protein-free medium.
Anticancer Res. 11:1591–1595. 1991.PubMed/NCBI
|
|
19.
|
Ahmed SA, Gogal RM Jr and Walsh JE: A new
rapid and simple non-radioactive assay to monitor and determine the
proliferation of lymphocytes: an alternative to
[3H]thymidine incorporation assay. J Immunol Methods.
170:211–224. 1994.PubMed/NCBI
|
|
20.
|
Nociari MM, Shalev A, Benias P and Russo
C: A novel one-step, highly sensitive fluorometric assay to
evaluate cell-mediated cytotoxicity. J Immunol Methods.
213:157–167. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Lennartsson J, Wardega P, Engstrom U,
Hellman U and Heldin CH: Alix facilitates the interaction between
c-Cbl and platelet-derived growth factor beta-receptor and thereby
modulates receptor down-regulation. J Biol Chem. 281:39152–39158.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
McLeod HL, Kearns CM, Kuhn JG and Bruno R:
Evaluation of the linearity of docetaxel pharmacokinetics. Cancer
Chemother Pharmacol. 42:155–159. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Sethi VS, Jackson DV Jr, White DR, et al:
Pharmacokinetics of vincristine sulfate in adult cancer patients.
Cancer Res. 41:3551–3555. 1981.PubMed/NCBI
|
|
24.
|
Nemoto T, Ohashi K, Akashi T, Johnson JD
and Hirokawa K: Overexpression of protein tyrosine kinases in human
esophageal cancer. Pathobiology. 65:195–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sines T, Granot-Attas S, Weisman-Welcher S
and Elson A: Association of tyrosine phosphatase epsilon with
microtubules inhibits phosphatase activity and is regulated by the
epidermal growth factor receptor. Mol Cell Biol. 27:7102–7112.
2007. View Article : Google Scholar
|
|
26.
|
Flint AJ, Tiganis T, Barford D and Tonks
NK: Development of ‘substrate-trapping’ mutants to identify
physiological substrates of protein tyrosine phosphatases. Proc
Natl Acad Sci USA. 94:1680–1685. 1997.
|
|
27.
|
Eden ER, White IJ, Tsapara A and Futter
CE: Membrane contacts between endosomes and ER provide sites for
PTP1B-epidermal growth factor receptor interaction. Nat Cell Biol.
12:267–272
|
|
28.
|
Poruchynsky MS, Wang EE, Rudin CM,
Blagosklonny MV and Fojo T: Bcl-xL is phosphorylated in malignant
cells following microtubule disruption. Cancer Res. 58:3331–3338.
1998.PubMed/NCBI
|
|
29.
|
Blagosklonny MV, Giannakakou P, el-Deiry
WS, et al: Raf-1/bcl-2 phosphorylation: a step from microtubule
damage to cell death. Cancer Res. 57:130–135. 1997.PubMed/NCBI
|
|
30.
|
Tarcic G, Boguslavsky SK, Wakim J, et al:
An unbiased screen identifies DEP-1 tumor suppressor as a
phosphatase controlling EGFR endocytosis. Curr Biol. 19:1788–1798.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Xu Y, Tan L-J, Grachtchouk V, Voorhees JJ
and Fisher GJ: Receptor-type protein-tyrosine phosphatase-kappa
regulates epidermal growth factor receptor function. J Biol Chem.
280:42694–42700. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Suarez Pestana E, Tenev T, Gross S,
Stoyanov B, Ogata M and Bohmer FD: The transmembrane protein
tyrosine phosphatase RPTPsigma modulates signaling of the epidermal
growth factor receptor in A431 cells. Oncogene. 18:4069–4079.
1999.PubMed/NCBI
|
|
33.
|
Keilhack H, Tenev T, Nyakatura E, et al:
Phosphotyrosine 1173 mediates binding of the protein-tyrosine
phosphatase SHP-1 to the epidermal growth factor receptor and
attenuation of receptor signaling. J Biol Chem. 273:24839–24846.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Agazie YM and Hayman MJ: Development of an
efficient ‘substrate-trapping’ mutant of Src homology
phosphotyrosine phosphatase 2 and identification of the epidermal
growth factor receptor, Gab1, and three other proteins as target
substrates. J Biol Chem. 278:13952–13958. 2003.
|
|
35.
|
Yuan T, Wang Y, Zhao ZJ and Gu H:
Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and
epidermal growth factor receptor signaling in breast cancer cells.
J Biol Chem. 285:14861–14870. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Ku GY and Ilson DH: Esophagogastric
cancer: targeted agents. Cancer Treat Rev. 36:235–248. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Ekman S, Dreilich M, Lennartsson J, et al:
Esophageal cancer: current and emerging therapy modalities. Expert
Rev Anticancer Ther. 8:1433–1448. 2008. View Article : Google Scholar : PubMed/NCBI
|
